​Dr. Faris Haddad

Abstract

A study in seven Middle Eastern and African countries assessed pharmacotherapy in patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease (eASCVD) or high ASCVD risk. Among 3,726 patients, 21% had eASCVD, with 69% at high risk. About 36% of patients received SGLT2 inhibitors, while only 13% received GLP-1 receptor agonists. SGLT2 inhibitor usage varied by duration of T2D and HbA1c levels, while GLP-1 RA usage was higher in females and those with obesity. The findings highlight the need for improved adoption of cardio-renal protective therapies in managing these patients, given the high burden of disease and complications in the region.​